Moderna will not invest in new late-stage vaccine trials due to growing opposition to immunizations from US officials, Chief Executive Officer Stéphane Bancel announced at the World Economic Forum in Davos, Switzerland.”You cannot make a return on investment if you don’t have access to the US market,” Bancel told Bloomberg TV on Wednesday, explaining that regulatory delays and lack of support from US health officials are making the potential market size “much smaller.”
Leave a Reply